Literature DB >> 20947261

Combination therapy targeting cancer metabolism.

Justin B Wenger1, Sang Y Chun, Duyen T Dang, Hendrik Luesch, Long H Dang.   

Abstract

Cancer cells undergo significant metabolic adaptation. Cellular transformation enhances both glycolysis and mitochondrial respiration efficiency through the induction of HIF-1α and HIF-2α. In this process, energy production and synthesis of macromolecules are maximized with minimal ROS accumulation. Furthermore, a series of antioxidant enzymes are induced to mitigate the damaging effects of ROS. Examination of these metabolic changes provides rationale for a synergistic approach to combination anti-cancer therapy; targeted inhibition of HIF and inhibition of cellular defenses against oxidative stress. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947261      PMCID: PMC3235410          DOI: 10.1016/j.mehy.2010.09.008

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  47 in total

1.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

Review 2.  Hypoxia--a key regulatory factor in tumour growth.

Authors:  Adrian L Harris
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

3.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.

Authors:  H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

4.  Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Authors:  M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

5.  p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

Authors:  D E Richard; E Berra; E Gothié; D Roux; J Pouysségur
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

6.  Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

Authors:  T Kamura; S Sato; K Iwai; M Czyzyk-Krzeska; R C Conaway; J W Conaway
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

7.  Loss of PTEN facilitates HIF-1-mediated gene expression.

Authors:  W Zundel; C Schindler; D Haas-Kogan; A Koong; F Kaper; E Chen; A R Gottschalk; H E Ryan; R S Johnson; A B Jefferson; D Stokoe; A J Giaccia
Journal:  Genes Dev       Date:  2000-02-15       Impact factor: 11.361

Review 8.  Peroxiredoxin 1 and its role in cell signaling.

Authors:  Carola A Neumann; Juxiang Cao; Yefim Manevich
Journal:  Cell Cycle       Date:  2009-12-05       Impact factor: 4.534

9.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

10.  Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism.

Authors:  Jian Chen; Songji Zhao; Kunihiro Nakada; Yuji Kuge; Nagara Tamaki; Futoshi Okada; Jingxin Wang; Masanobu Shindo; Fumihiro Higashino; Kohji Takeda; Masahiro Asaka; Hiroyuki Katoh; Toshio Sugiyama; Masuo Hosokawa; Masanobu Kobayashi
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

View more
  8 in total

Review 1.  Metabolomics in rheumatic diseases: desperately seeking biomarkers.

Authors:  Monica Guma; Stefano Tiziani; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2016-03-03       Impact factor: 20.543

2.  Reactive Secondary Sequence Oxidative Pathology Polymer Model and Antioxidant Tests.

Authors:  Richard C Petersen
Journal:  Int Res J Pure Appl Chem       Date:  2012

3.  Free-radicals and advanced chemistries involved in cell membrane organization influence oxygen diffusion and pathology treatment.

Authors:  Richard C Petersen
Journal:  AIMS Biophys       Date:  2017-04-06

Review 4.  Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.

Authors:  Varda Shoshan-Barmatz; Yakov Krelin; Anna Shteinfer-Kuzmine; Tasleem Arif
Journal:  Front Oncol       Date:  2017-07-31       Impact factor: 6.244

5.  VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress.

Authors:  Varda Shoshan-Barmatz; Eduardo N Maldonado; Yakov Krelin
Journal:  Cell Stress       Date:  2017-10-01

6.  Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells.

Authors:  Tasleem Arif; Zohar Amsalem; Varda Shoshan-Barmatz
Journal:  Mol Ther Nucleic Acids       Date:  2019-05-18       Impact factor: 8.886

Review 7.  Free-radical polymer science structural cancer model: a review.

Authors:  Richard C Petersen
Journal:  Scientifica (Cairo)       Date:  2013-03-04

8.  Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept.

Authors:  Tasleem Arif; Oriel Stern; Srinivas Pittala; Vered Chalifa-Caspi; Varda Shoshan-Barmatz
Journal:  Cells       Date:  2019-10-28       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.